A retrospective analysis of locally advanced EGFR-mutated NSCLC patients with durvalumab after chemoradiotherapy

被引：0
|
作者：
Uchida, Yoshiyasu [1 ]
Ninomiya, Takashi [1 ]
Harada, Daijiro [1 ]
Kozuki, Toshiyuki [1 ]
机构：
[1] Natl Hosp Org Shikoku Canc Ctr, Dept Thorac Oncol & Med, Matsuyama, Ehime, Japan
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.05.126
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MO11-4
引用
收藏
页码：S488 / S488
页数：1
相关论文
共 50 条
  • [1] Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
    Aredo, Jacqueline V.
    Mambetsariev, Isa
    Hellyer, Jessica A.
    Amini, Arya
    Neal, Joel W.
    Padda, Sukhmani K.
    McCoach, Caroline E.
    Riess, Jonathan W.
    Cabebe, Elwyn C.
    Naidoo, Jarushka
    Abuali, Tariq
    Salgia, Ravi
    Loo Jr, Billy W.
    Diehn, Maximilian
    Han, Summer S.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (06) : 1030 - 1041
  • [2] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Banna, Giuseppe Luigi
    Addeo, Alfredo
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (16): : 1555 - 1556
  • [3] Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
    Lu, Shun
    Kato, Terufumi
    Dong, Xiaorong
    Ahn, Myung-Ju
    Quang, Le-Van
    Soparattanapaisarn, Nopadol
    Inoue, Takako
    Wang, Chih-Liang
    Huang, Meijuan
    Yang, James Chih-Hsin
    Cobo, Manuel
    Ozguroglu, Mustafa
    Casarini, Ignacio
    Khiem, Dang-Van
    Sriuranpong, Virote
    Cronemberger, Eduardo
    Takahashi, Toshiaki
    Runglodvatana, Yotsawaj
    Chen, Ming
    Huang, Xiangning
    Grainger, Ellie
    Ghiorghiu, Dana
    van der Gronde, Toon
    Ramalingam, Suresh S.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024,
  • [4] Osimertinib in EGFR-Mutated Advanced NSCLC
    Yan, Kelvin
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1863 - 1863
  • [5] A retrospective analysis of tolerability in EGFR-mutated NSCLC patients who received afatinib
    Koriyama, Haruki
    Yoh, Kiyotaka
    Kirita, Keisuke
    Umemura, Shigeki
    Matsumoto, Shingo
    Niho, Seiji
    Ohmatsu, Hironobu
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2015, 26 : 137 - 137
  • [6] Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
    He, J.
    Gao, S.
    Reck, M.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Lee, K. -Y.
    Horio, Y.
    Runglodvatana, Y.
    Aperghis, M.
    Doherty, G. J.
    Laud, P. J.
    Fouad, T. M.
    Heymach, J. V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S72 - S73
  • [7] Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
    Faehling, Martin
    Schumann, Christian
    Christopoulos, Petros
    Hoffknecht, Petra
    Alt, Jurgen
    Horn, Marlitt
    Eisenmann, Stephan
    Schlenska-Lange, Anke
    Schutt, Philipp
    Steger, Felix
    Bruckl, Wolfgang M.
    Christoph, Daniel C.
    DATA IN BRIEF, 2021, 34
  • [8] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
  • [9] Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC
    Planchard, D.
    Janne, P. A.
    Cheng, Y.
    Yang, J. C. -H.
    Yanagitani, N.
    Kim, S-W
    Sugawara, S.
    Yu, Y.
    Fan, Y.
    Geater, S. L.
    Laktionov, K.
    Lee, C. K.
    Valdiviezo, N.
    Ahmed, S.
    Maurel, J-M
    Andrasina, I
    Goldman, J.
    Ghiorghiu, D.
    Rukazenkov, Y.
    Todd, A.
    Kobayashi, K.
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (21): : 1935 - 1948
  • [10] Clinical analysis of the presence of comutations in patients with EGFR-mutated NSCLC
    Rubio, Jaime
    Santolaya, Carlota
    Fernandez, Marina
    Villalba, Paula Lucia
    Avedillo, Mercedes
    Garcia-Foncillas, Jesus
    Domine, Manuel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345